

Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)

Meeting – July 9, 2014 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. June 11, 2014 DUR Minutes – Vote
- B. June 11, 2014 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Update of Medication Coverage Authorization Unit/Opioid RetroDUR – See Appendix B

- A. Medication Coverage Activity for June 2014
- B. Pharmacy Help Desk Activity for June 2014
- C. Opioid Prescriptions in Pregnant Women
- D. Concomitant Benzodiazepine and Opioid Utilization

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Esomeprazole Strontium and Aciphex[®] Sprinkle[™] (Rabeprazole) – See Appendix C

- A. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Liptruzet[™] (Ezetimibe/Atorvastatin) and Omtryg[™] (Omega-3-Acid Ethyl Esters A) – See Appendix D

- A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Zecuity[®] (Sumatriptan Iontophoretic Transdermal System) – See Appendix E

- A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

8. Action Item – Annual Review of Relistor[®] (Methylnaltrexone), Linzess[®] (Linaclotide), and Amitiza[®] (Lubiprostone) – See Appendix F

- A. Current Authorization Criteria

- B. Utilization of Relistor[®], Linzess[®], and Amitiza[®]
- C. Prior Authorization
- D. Market News and Updates
- E. COP Recommendations
- F. Utilization Details

Items to be presented by Dr. Anderson, Dr. Muchmore, Chairman:

9. Annual Review of Anticoagulants and Platelet Aggregation Inhibitors and 30-Day Notice to Prior Authorize Zontivity[™] (Vorapaxar) – See Appendix G

- A. Current Authorization Criteria
- B. Utilization of Anticoagulants and Platelet Aggregation Inhibitors
- C. Prior Authorization
- D. Market News and Updates
- E. Summary
- F. COP Recommendations
- G. Utilization Details
- H. Product Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

10. Annual Review of Opioid Analgesics and 30-Day Notice to Prior Authorize Zohydro[™] ER (Hydrocodone Bitartrate) and Xartemis[™] XR (Oxycodone/Acetaminophen) – See Appendix H

- A. Current Authorization Criteria
- B. Utilization of Opioid Analgesics
- C. Prior Authorization
- D. Utilization Trend
- E. Market News and Updates
- F. Summary
- G. COP Recommendations
- H. Utilization Details

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

11. Action Item – Annual Review of Xolair[®] (Omalizumab) – See Appendix I

- A. Introduction
- B. Current Prior Authorization
- C. Utilization of Xolair[®]
- D. Prior Authorization
- E. Summary
- F. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

12. FDA and DEA Updates – See Appendix J

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

13. Future Business

- A. Annual Reviews
- B. New Product Reviews

Items to be presented by Dr. Muchmore, Chairman:

14. Adjournment